Get the Stockscreener App
2.12
16.54%
-0.42
After Hours:
2.05
-0.07
-3.30%
Profusa Inc stock is traded at $2.12, with a volume of 230.53K.
It is down -16.54% in the last 24 hours and up +752.43% over the past month.
Profusa Inc is a clinical-stage digital health and medical technology company. The Company's technology enables the development of bioengineered sensors that are designed to become one with the body to detect and continuously transmit actionable, clinical-grade data for personal and medical use. The Company's first offering in the European Union, the Lumee Oxygen Platform, is designed to report reliable tissue oxygen levels at various regions of interest, both acutely and long-term. The Lumee Oxygen Platform has been designed for use in applications where monitoring of compromised tissue is beneficial, such as peripheral artery disease that results in narrowing of blood vessels and reduced blood flow to the lower limbs; chronic wounds that do not heal properly; and reconstructive surgery.
See More
Previous Close:
$2.54
Open:
$2.49
24h Volume:
230.53K
Relative Volume:
0.08
Market Cap:
$1.12M
Revenue:
$75,000
Net Income/Loss:
$-42.41M
P/E Ratio:
-0.0118
EPS:
-179.8206
Net Cash Flow:
$-18.47M
1W Performance:
+2,167%
1M Performance:
+752.43%
6M Performance:
-69.99%
1Y Performance:
+0.00%
1-Day Range:
$1.93
$2.4999
1-Week Range:
$0.089
$3.01
52-Week Range:
$0.0801
$166.50
Profusa Inc Stock (PFSA) Company Profile
Name
Profusa Inc
Sector
Industry
Phone
212-494-9022
Address
207 WEST 25TH ST, 9TH FLOOR, NEW YORK
Compare PFSA vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
PFSA
Profusa Inc
|
2.12 | 1.12M | 75,000 | -42.41M | -18.47M | -179.82 |
ABT
Abbott Laboratories
|
93.93 | 163.61B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
329.78 | 126.42B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.87 | 107.36B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
44.77 | 66.54B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
92.21 | 53.09B | 6.30B | 1.07B | 1.09B | 1.8406 |
Profusa Inc Stock (PFSA) Latest News
Profusa Stock Short Interest Rises to 44.46% - Quiver Quantitative
Why Did PFSA Stock Surge 150% Today? - Stocktwits
Profusa files resale prospectus for up to 7,170,891 shares - scanx.trade
Profusa (PFSA) registers 23,194 resale shares; 1-for-25 reverse split cut float - Stock Titan
Profusa (PFSA) registers 7.17M resale shares and effects 1:25 reverse split - Stock Titan
Profusa (NASDAQ: PFSA) resale 118,518 conversion shares after 1:25 split - Stock Titan
Profusa Announces 1-for-25 Reverse Stock Split Effective July 7, 2026 to Maintain Nasdaq Listing - Minichart
Profusa Implements 1-for-25 Reverse Stock Split on Nasdaq - TipRanks
Profusa (NASDAQ: PFSA) enacts 1-for-25 reverse stock split, cuts share count - Stock Titan
Profusa announces reverse stock split - Medical Buyer
PFSA Should I Buy - Intellectia AI
Profusa approves 1-for-25 reverse stock split; shares tumble - MSN
This Biotech Stock Crashed 28% Today After Announcing Second Reverse Share Split This Year - Asianet Newsable
11 Health Care Stocks Moving In Thursday's Intraday Session - Benzinga
Profusa announces 1-for-25 reverse stock split effective July 7 - Investing.com Australia
Profusa Announces 1-for-25 Reverse Stock Split Effective July 7, 2026 - Quiver Quantitative
Profusa to cut shares 25-to-1 before Nasdaq trading opens July 7 - Stock Titan
Enterprise value to revenue forward of Profusa, Inc. – NASDAQ:PFSA - TradingView
Price to book forward of Profusa, Inc. – NASDAQ:PFSA - TradingView
Price to earnings forward of Profusa, Inc. – NASDAQ:PFSA - TradingView
Profusa Company Profile & Introduction - Moomoo
At the 2026 annual meeting, Profusa Inc’s shareholders formally approved a series of key strategic initiatives. - Bitget
Which stocks are most active on Wednesday? - ChartMill
Profusa Shareholders Approve Reverse Split and Governance Changes - The Globe and Mail
Profusa shareholders approve acquisition, debt conversion proposals By Investing.com - Investing.com South Africa
Profusa (NASDAQ:PFSA) Advances Biosensing and Diagnostics Expansion - Kalkine Media
Profusa shareholders approve acquisition, debt conversion proposals - Investing.com
Profusa wins shareholder backing for PanOmics deal and Nasdaq push - Stock Titan
Profusa shareholders approve acquisition of PanOmics and reverse split - scanx.trade
Form 8K Profusa Inc For: 23 June By Investing.com - Investing.com South Africa
Profusa stockholders approve board proposals including director election and reverse split authorization - Investing.com UK
Profusa (PFSA) wins approval for reverse split, asset deal stock and larger equity plan - Stock Titan
Profusa submits response to European regulator for device approval - Investing.com UK
Profusa submits response to European regulator for device approval By Investing.com - Investing.com Canada
Profusa Submits Response Package to GMED as Part of Ongoing CE Mark Review Process for Lumee® Oxygen Platform - The Manila Times
Profusa Submits Response Package to GMED as Part of Ongoing Ce Mark Review Process for Lumee Oxygen Platform - marketscreener.com
Profusa submits response package to GMED for CE Mark review - scanx.trade
Profusa CEO urges shareholders to vote on Nasdaq listing proposals By Investing.com - Investing.com Nigeria
Profusa CEO urges shareholders to vote on Nasdaq listing proposals - Investing.com
Profusa Issues Letter to Shareholders Encouraging Shareholders to Vote FOR All Proposals at June 23, 2026 Annual Meeting - The Manila Times
Profusa Issues Letter to Shareholders Encouraging - GlobeNewswire
Profusa, Inc. Files 8-K: Advance Notice for Common Stock Purchase Under Equity Line Agreement with Ascent Partners, Nasdaq Listed (PFSA) - Minichart
Profusa (NASDAQ: PFSA) registers 179.3M shares; Ascent holds majority - Stock Titan
Profusa Taps Equity Line With Dilutive True-Up Mechanism - TipRanks
Profusa Inc Stock (PFSA) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.36%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):